Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,287 | 95 | 41.8% |
| Unspecified | $2,900 | 1 | 36.9% |
| Travel and Lodging | $1,670 | 12 | 21.2% |
| Education | $3.33 | 3 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $2,949 | 4 | $0 (2023) |
| Daiichi Sankyo Inc. | $1,055 | 42 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $1,010 | 9 | $0 (2022) |
| UCB GmBH | $914.36 | 13 | $0 (2020) |
| Ironwood Pharmaceuticals, Inc | $671.50 | 3 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $593.39 | 16 | $0 (2022) |
| Janssen Biotech, Inc. | $316.19 | 14 | $0 (2024) |
| Esperion Therapeutics, Inc. | $125.00 | 1 | $0 (2022) |
| Biohaven Pharmaceutical Holding Company Ltd. | $120.45 | 2 | $0 (2022) |
| Novo Nordisk Inc | $33.90 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $226.79 | 11 | Janssen Biotech, Inc. ($154.74) |
| 2023 | $3,075 | 9 | PFIZER INC. ($2,900) |
| 2022 | $1,599 | 28 | Alnylam Pharmaceuticals Inc. ($1,010) |
| 2021 | $532.27 | 18 | Daiichi Sankyo Inc. ($421.50) |
| 2020 | $1,095 | 23 | UCB GmBH ($914.36) |
| 2019 | $315.05 | 11 | Daiichi Sankyo Inc. ($164.78) |
| 2018 | $958.19 | 8 | Ironwood Pharmaceuticals, Inc ($671.50) |
| 2017 | $58.08 | 3 | Daiichi Sankyo Inc. ($36.18) |
All Payment Transactions
111 individual payment records from CMS Open Payments — Page 5 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2018 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $116.59 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2018 | Novartis Pharmaceuticals Corporation | JADENU (Drug) | Food and Beverage | In-kind items and services | $124.22 | General |
| Category: HEMATOLOGY | ||||||
| 07/18/2018 | PFIZER INC. | XALKORI (Drug), IBRANCE | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: ONCOLOGY | ||||||
| 04/19/2018 | PFIZER INC. | XALKORI (Drug), IBRANCE | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: ONCOLOGY | ||||||
| 04/07/2018 | Ironwood Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $296.62 | General |
| 04/07/2018 | Ironwood Pharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $206.88 | General |
| 04/07/2018 | Ironwood Pharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $168.00 | General |
| 02/14/2018 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $11.10 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2017 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2017 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: Anemia | ||||||
| 02/15/2017 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: Anemia | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $2,900 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 110 | 271 | $66,867 | $27,603 |
| 2022 | 2 | 92 | 220 | $54,257 | $22,008 |
| 2021 | 3 | 94 | 219 | $53,432 | $21,503 |
| 2020 | 3 | 113 | 231 | $58,006 | $20,151 |
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 182 | $40,768 | $16,458 | 40.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 75 | $22,725 | $9,466 | 41.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 14 | 14 | $3,374 | $1,679 | 49.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 63 | 157 | $35,168 | $13,949 | 39.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 63 | $19,089 | $8,060 | 42.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 66 | 185 | $41,440 | $16,713 | 40.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 15 | 21 | $6,363 | $2,594 | 40.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $5,629 | $2,196 | 39.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 72 | 183 | $40,992 | $14,382 | 35.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 22 | 29 | $8,787 | $2,898 | 33.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 19 | 19 | $8,227 | $2,871 | 34.9% |
About Dr. Renae Mayer, M.D
Dr. Renae Mayer, M.D is a Internal Medicine healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093752503.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Renae Mayer, M.D has received a total of $7,860 in payments from pharmaceutical and medical device companies, with $226.79 received in 2024. These payments were reported across 111 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($3,287).
As a Medicare-enrolled provider, Mayer has provided services to 409 Medicare beneficiaries, totaling 941 services with total Medicare billing of $91,265. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Tulsa, OK
- Active Since 06/01/2006
- Last Updated 07/30/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1093752503
Products in Payments
- NURTEC ODT (Drug) $3,020
- INJECTAFER (Drug) $1,032
- PROMACTA (Drug) $318.15
- RYBREVANT (Drug) $154.74
- NEXLIZET (Drug) $125.00
- JADENU (Drug) $124.22
- GLEEVEC (Drug) $109.54
- XALKORI (Drug) $34.78
- Enhertu (Drug) $22.77
- ENTRESTO (Drug) $20.76
- SCEMBLIX (Drug) $20.72
- Saxenda (Drug) $19.81
- Livalo (Drug) $18.45
- IBRANCE (Drug) $14.71
- Horizant (Drug) $14.11
- Rybelsus (Drug) $14.09
- (5044) MCOT (Device) $13.90
- UBRELVY (Drug) $12.62
- BOTOX COSMETIC (Biological) $11.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tulsa
Dr. Anuj Malik, Md, MD
Internal Medicine — Payments: $559,128
Mousumi Som, Do, DO
Internal Medicine — Payments: $182,416
Madhuri Lad, D.o, D.O
Internal Medicine — Payments: $160,090
Jesse Richards, D.o, D.O
Internal Medicine — Payments: $147,415
Dr. Stacy Chronister, D.o, D.O
Internal Medicine — Payments: $118,921
Mr. Eugene Ichinose, M.d, M.D
Internal Medicine — Payments: $113,876